American Association for Cancer Research
00085472can142030-sup-134451_1_supp_2672098_nccvkt.docx (16.65 kB)

Supplementary Table S2 from Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia

Download (16.65 kB)
journal contribution
posted on 2023-03-30, 22:49 authored by Bérengère Vire, Martin Skarzynski, Joshua D. Thomas, Christopher G. Nelson, Alexandre David, Georg Aue, Terrence R. Burke, Christoph Rader, Adrian Wiestner

This table describes relapsed or refractory patients characteristics.



Chronic lymphocytic leukemia (CLL) is a B-cell malignancy in need of new, effective, and safe therapies. The recently identified IgM receptor FcμR is overexpressed on malignant B cells in CLL and mediates the rapid internalization and lysosomal shuttling of IgM via its Fc fragment (Fcμ). To exploit this internalization and trafficking pathway for targeted drug delivery, we engineered an IgM-derived protein scaffold (Fcμ) and linked it with the cytotoxic agent monomethylauristatin F. This Fcμ–drug conjugate was selectively toxic for FcμR-expressing cell lines in vitro and for CLL cells but not autologous normal T cells ex vivo. Notably, the cytotoxic activity of the Fcμ–drug conjugate was maintained in CLL cells carrying a 17p deletion, which predicts resistance to standard chemotherapy. Next, we tested the possible therapeutic application of the Fcμ–drug conjugate in immunodeficient NOD/SCID/IL-2Rγnull (NSG) mice engrafted with peripheral blood cells from patients with leukemia. Three intravenous injections of the Fcμ–drug conjugate over a 10-day period were well tolerated and selectively killed the human CLL cells but not the coengrafted autologous human T cells. In summary, we developed a novel strategy for targeted cytotoxic therapy of CLL based on the unique properties of FcμR. FcμR-targeted drug delivery showed potent and specific therapeutic activity in CLL, thus providing proof of concept for FcμR as a valuable therapeutic target in CLL and for IgM-based antibody–drug conjugates as a new targeting platform. Cancer Res; 74(24); 7510–20. ©2014 AACR.